SCHEMBL1300290

SCHEMBL1300290

COc1nc2c(cc1NCc1ccc(F)cc1)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.43
▸ KCNQ3 O43525 1/20 0.37
▸ KCNQ2 O43526 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ GPR35 Q9HC97 1/20 0.36
▸ CISD1 Q9NZ45 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ASPH Q12797 1/20 0.35
▸ RIOX2 Q8IUF8 1/20 0.35
▸ KDM8 Q8N371 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ F2 P00734 1/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ RXFP1 Q9HBX9 3/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1300294 1.00 METTL3 (0.43) METTL3KCNQ3KCNQ2MEN1KMT2A
SCHEMBL1300666 0.92 METTL3 (0.42) METTL3KDM4EASPHRIOX2KDM8
SCHEMBL1300668 0.92 METTL3 (0.42) METTL3KDM4EASPHRIOX2KDM8
SCHEMBL1301351 0.92 METTL3 (0.40) METTL3MEN1KMT2AKDM4EASPH
SCHEMBL1301348 0.92 METTL3 (0.40) METTL3MEN1KMT2AKDM4EASPH
SCHEMBL1300646 0.92 METTL3 (0.44) METTL3MEN1KMT2AKDM4EASPH
SCHEMBL1300641 0.92 METTL3 (0.44) METTL3MEN1KMT2AKDM4EASPH
SCHEMBL1300902 0.92 METTL3 (0.42) METTL3KMT2AKDM4EPIM1RXFP1
SCHEMBL1300860 0.92 METTL3 (0.42) METTL3KDM4EASPHRIOX2KDM8
SCHEMBL1300908 0.92 METTL3 (0.42) METTL3KMT2AKDM4EPIM1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885KCNQ3 4581/4885KCNQ2 4605/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885KCNQ3 4581/4885KCNQ2 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback